|By Business Wire||
|June 17, 2014 05:29 AM EDT||
Delphi Genetics SA has announced today a new license agreement for the use of the StabyExpress® technology in the food industry. The technology will be used for the production of enzymes for food processing.
Under the agreement, the company receives a non-exclusive worldwide license to use the StabyExpress™ technology for enzyme production in GMP conditions. In exchange, Delphi is eligible to receive upfront and milestone payments associated with the development of the product that utilize the StabyExpress® technology, as well as royalties on sales of such product.
Cédric Szpirer PhD, Delphi Genetics Founder and CEO, explained: “This is Delphi's first licensing agreement that covers the use of the StabyExpress® technology for protein production in the field of food industry. It is an additional proof that the technology is usable for any production of recombinant protein in E. coli including pharmaceutical bioproductions and industrial biotechnology. The StabyExpress® technology allows to produce (i) higher yields of recombinant proteins and (ii) without the use of antibiotic resistance genes. These advantages were clearly identified by our new partner. The non-exclusive nature of this agreement enables us to consider similar collaborations with other strategic partners.”
Previously, Delphi Genetics announced existing licensing agreements with Sanofi-Pasteur, GSK and a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada.
StabyExpress® technology can be applied to any industrial protein production process that involves bacterial fermentation. Moreover, the technology is in line with the recommendations of the FDA, USDA and EMA with regard to the elimination of antibiotic resistance genes in protein production processes for both human and veterinary uses. The technology is also usable to produce DNA vaccines in order to avoid completely the use of antibiotics resistance genes.
About Delphi Genetics SA
Founded in 2001, Delphi Genetics develops technologies for DNA and protein productions (including antibodies) by using its unique expertise in the field of plasmid stabilisation systems. Delphi Genetics’ patented StabyExpress® technology increases the yield of recombinant protein or pDNA productions in E. coli without the use of antibiotics, which is the traditional approach. Delphi Genetics is also involved in several research projects including the use of Staby® for the development of DNA vaccines, the adaptation of the technology to mammalian cells and development of antibodies. Delphi Genetics offers licenses, products and value-added services based on its technologies and expertise.
Regarding services, Delphi Genetics provides custom services in genetic engineering in E. coli and mammalian cells, development and productions of proteins, pDNA and antibodies. Antibody development is based on a brand new technology allowing unique antigen presentation to the immune system combined to DNA immunization. Using this method, Delphi Genetics is able to develop antibodies even against self-antigens.
For further information, please visit our website: www.delphigenetics.com
"AgilData is the next generation of dbShards. It just adds a whole bunch more functionality to improve the developer experience," noted Dan Lynn, CEO of AgilData, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Jul. 6, 2015 09:00 AM EDT Reads: 1,323
Jul. 6, 2015 09:00 AM EDT Reads: 436
SYS-CON Events announced today that Cloudian, Inc., the leading provider of hybrid cloud storage solutions, will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Cloudian, Inc., is a Foster City, California - based software company specializing in cloud storage software. The main product is Cloudian, an Amazon S3-compliant cloud object storage platform, the bedrock of cloud computing system...
Jul. 6, 2015 09:00 AM EDT Reads: 1,983
Containers are revolutionizing the way we deploy and maintain our infrastructures, but monitoring and troubleshooting in a containerized environment can still be painful and impractical. Understanding even basic resource usage is difficult – let alone tracking network connections or malicious activity. In his session at DevOps Summit, Gianluca Borello, Sr. Software Engineer at Sysdig, will cover the current state of the art for container monitoring and visibility, including pros / cons and liv...
Jul. 6, 2015 09:00 AM EDT Reads: 1,723
Jul. 6, 2015 08:45 AM EDT Reads: 1,650
Jul. 6, 2015 08:45 AM EDT Reads: 1,794
Jul. 6, 2015 08:15 AM EDT Reads: 1,519
Jul. 6, 2015 08:00 AM EDT Reads: 1,557
Jul. 6, 2015 07:30 AM EDT Reads: 1,559
Jul. 6, 2015 07:15 AM EDT Reads: 1,598
Jul. 6, 2015 05:30 AM EDT Reads: 2,242
Jul. 6, 2015 05:00 AM EDT Reads: 1,561
Jul. 6, 2015 03:00 AM EDT Reads: 2,450
Jul. 6, 2015 02:45 AM EDT Reads: 2,766
Jul. 5, 2015 08:00 PM EDT Reads: 1,686